EADO 2022 | Could locally advanced SCC be treated for a shorter duration in an elderly population?

Squamous cell carcinoma (SCC) particularly effects the elderly and fragile population. Iris Zalaudek, MD, PhD, Dermatology Clinic, University of Trieste, Maggiore Hospital, Trieste, Italy, discusses data on two elderly patients with SCC. The PD-1 antibody, cemiplimab, is currently approved for SCC treatment. The patients exhibited a highly rapid response following the third cycle, and following this decided to ceased treatment. Both patients demonstrated a long-term complete response (CR). This data provides the grounds to further investigate whether patients with SCC who are elderly or fragile could be treated for a shorter duration and avoid unnecessary toxicities. This interview took place at the EADO 2022 congress.